EP1175228A4 - Gene therapy using tgf-beta - Google Patents

Gene therapy using tgf-beta

Info

Publication number
EP1175228A4
EP1175228A4 EP00925522A EP00925522A EP1175228A4 EP 1175228 A4 EP1175228 A4 EP 1175228A4 EP 00925522 A EP00925522 A EP 00925522A EP 00925522 A EP00925522 A EP 00925522A EP 1175228 A4 EP1175228 A4 EP 1175228A4
Authority
EP
European Patent Office
Prior art keywords
tgf
beta
gene therapy
therapy
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP00925522A
Other languages
German (de)
French (fr)
Other versions
EP1175228A1 (en
Inventor
Moon Jong Noh
Kyoung Ae Kang
Kwan Hee Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kolon TissueGene Inc
Original Assignee
TissueGene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1019990015854A external-priority patent/KR20000072904A/en
Priority claimed from US09/345,415 external-priority patent/US6315992B1/en
Application filed by TissueGene Inc filed Critical TissueGene Inc
Publication of EP1175228A1 publication Critical patent/EP1175228A1/en
Publication of EP1175228A4 publication Critical patent/EP1175228A4/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP00925522A 1999-05-03 2000-05-03 Gene therapy using tgf-beta Ceased EP1175228A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR9915854 1999-05-03
KR1019990015854A KR20000072904A (en) 1999-05-03 1999-05-03 An agent for treating ligament damage and repairing articular cartilage defects comprising TGF-β secreting cell
US09/345,415 US6315992B1 (en) 1999-06-30 1999-06-30 Generating cartilage in a mammal using fibroblasts transfected with a vector encoding TGF-β-1
US345415 1999-06-30
PCT/IB2000/000653 WO2000066177A1 (en) 1999-05-03 2000-05-03 GENE THERAPY USING TGF-$g(b)

Publications (2)

Publication Number Publication Date
EP1175228A1 EP1175228A1 (en) 2002-01-30
EP1175228A4 true EP1175228A4 (en) 2003-02-26

Family

ID=26635050

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00925522A Ceased EP1175228A4 (en) 1999-05-03 2000-05-03 Gene therapy using tgf-beta

Country Status (7)

Country Link
EP (1) EP1175228A4 (en)
JP (3) JP4592186B2 (en)
KR (1) KR100702725B1 (en)
CN (2) CN1371289B (en)
AU (1) AU778047B2 (en)
CA (1) CA2373045C (en)
WO (1) WO2000066177A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002243307A1 (en) * 2000-11-08 2002-07-24 Tissuegene, Inc. Gene therapy using tgf-beta
KR100688871B1 (en) * 2002-03-12 2007-03-02 티슈진, 인코포레이티드 Cartilage regeneration using chondrocyte and tgf-?
US7005127B2 (en) * 2002-03-29 2006-02-28 Tissuegene, Inc. Mixed-cell gene therapy
AU2003251854A1 (en) * 2002-07-09 2004-01-23 Stryker Corporation Compositions and methods for ligament growth and repair
JP2006515765A (en) * 2002-11-15 2006-06-08 エスディージーアイ・ホールディングス・インコーポレーテッド Collagen-based materials and methods for treating synovial joints
WO2005073365A1 (en) * 2004-01-29 2005-08-11 Japan Tissue Engineering Co., Ltd. Method of treating cells for transplantation, cell suspension, prosthesis for transplantation and method of treating injured site
EP3305326B1 (en) * 2008-03-21 2022-04-13 Kolon Tissuegene, Inc. Treatment of intervertebral disc degeneration
JP5388233B2 (en) * 2011-01-19 2014-01-15 富士ソフト株式会社 Method for evaluating the cartilage characteristics of regenerated cartilage
US10793625B2 (en) * 2012-05-01 2020-10-06 The Johns Hopkins University Compositions and methods for treating or preventing osteoarthritis
CA2923857A1 (en) * 2013-09-09 2015-03-12 Figene, Llc Gene therapy for the regeneration of chondrocytes or cartilage type cells
SG11201913793SA (en) 2017-06-30 2020-01-30 Kolon Life Science Inc Method for assessing validity of cell therapy product
CN113372432A (en) * 2021-06-15 2021-09-10 深圳市臻质医疗科技有限公司 Method for inducing and/or enhancing cartilage injury repair based on chemically modified mRNA coding protein factor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858355A (en) * 1990-12-20 1999-01-12 University Of Pittsburgh Of The Commonwealth System Of Higher Education IRAP gene as treatment for arthritis
US6315992B1 (en) * 1999-06-30 2001-11-13 Tissuegene Co. Generating cartilage in a mammal using fibroblasts transfected with a vector encoding TGF-β-1

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413511B1 (en) * 1990-12-20 2002-07-02 University Of Pittsburgh Of The Commonwealth System Of Higher Education Cartilage alterations by administering to joints chondrocytes comprising a heterologous polynucleotide
US5869041A (en) * 1996-01-12 1999-02-09 The Miriam Hospital Delivery of bioactive compounds to an organism
US6077987A (en) * 1997-09-04 2000-06-20 North Shore-Long Island Jewish Research Institute Genetic engineering of cells to enhance healing and tissue regeneration
ATE369141T1 (en) * 1998-05-01 2007-08-15 Univ Pittsburgh CELL-MEDIATED GENE ADMINISTRATION BY USING MUSCLE-DERIVATED CELLS TO TREAT THE BONE-RELATED INJURY OR DISORDER

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858355A (en) * 1990-12-20 1999-01-12 University Of Pittsburgh Of The Commonwealth System Of Higher Education IRAP gene as treatment for arthritis
US6315992B1 (en) * 1999-06-30 2001-11-13 Tissuegene Co. Generating cartilage in a mammal using fibroblasts transfected with a vector encoding TGF-β-1

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO0066177A1 *

Also Published As

Publication number Publication date
JP2007008950A (en) 2007-01-18
JP2009019039A (en) 2009-01-29
AU4424200A (en) 2000-11-17
CA2373045C (en) 2016-07-26
JP4547446B2 (en) 2010-09-22
EP1175228A1 (en) 2002-01-30
JP2002542801A (en) 2002-12-17
CN101972275A (en) 2011-02-16
CA2373045A1 (en) 2000-11-09
JP4188986B2 (en) 2008-12-03
CN1371289B (en) 2013-03-20
AU778047B2 (en) 2004-11-11
JP4592186B2 (en) 2010-12-01
KR20020036943A (en) 2002-05-17
CN1371289A (en) 2002-09-25
KR100702725B1 (en) 2007-04-03
WO2000066177A1 (en) 2000-11-09

Similar Documents

Publication Publication Date Title
HK1200316A1 (en) Therapeutic microfoams
AU7680300A (en) Human dna sequences
HUP0201438A2 (en) Dna vaccine - pcv
GB9930570D0 (en) Therapy
EP1175228A4 (en) Gene therapy using tgf-beta
GB9907243D0 (en) Therapy
HUP0105208A3 (en) Gene therapy-1
IL146332A0 (en) PrP-LIKE GENE
AU2732000A (en) Reverse gene therapy
GB9924981D0 (en) Gene therapy
GB9900009D0 (en) Gene therapy
GB0406539D0 (en) Gene therapy
EP1215284A4 (en) Tsg-like gene
GB9905644D0 (en) Dna
AU4808200A (en) Dna balls
EP1231266A4 (en) Arabidopsis-origin gdp-4-keto-6-deoxy-d-mannose-3,5-epimerase-4-reductase gene
MXPA01012500A (en) Gene therapy products.
AU2002243307A1 (en) Gene therapy using tgf-beta
AU4552700A (en) Gene therapy
GB9910587D0 (en) Gene therapy
GB9920837D0 (en) Gene therapy
AU7543200A (en) Targeted gene therapy
GB0016585D0 (en) Syringe
GB0005841D0 (en) Gene therapy
GB0005846D0 (en) Gene therapy

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011130

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20030115

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 07K 14/495 B

Ipc: 7A 61K 38/18 B

Ipc: 7A 61K 48/00 A

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: TISSUEGENE, INC.

17Q First examination report despatched

Effective date: 20040205

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20061107

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1044118

Country of ref document: HK